<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59926">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325830</url>
  </required_header>
  <id_info>
    <org_study_id>CVP 1627-01</org_study_id>
    <nct_id>NCT02325830</nct_id>
  </id_info>
  <brief_title>CARILLON Mitral Contour System® for Reducing Functional Mitral Regurgitation</brief_title>
  <acronym>REDUCE FMR</acronym>
  <official_title>The REDUCE FMR Trial: Safety and Efficacy of the CARILLON Mitral Contour System® in Reducing Functional Mitral Regurgitation (FMR) Associated With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiac Dimensions Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Menzies Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiac Dimensions Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective, multi-center, randomized, double-blind trial is to assess
      the safety and efficacy of the CARILLON Mitral Contour System in treating functional mitral
      regurgitation (FMR) associated with heart failure, compared to a randomized Control group
      which is medically managed according to heart failure guidelines.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in regurgitant volume associated with the CARILLON device relative to the Control population</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Document the difference in the rate of major adverse events between Treatment (CARILLON) and Control groups</measure>
    <time_frame>30 days and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess rate of heart failure hospitalizations between Treatment (CARILLON) and Control groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the change in six-minute walk distance between Treatment (CARILLON) and Control groups</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the change in left ventricular volumes between Treatment (CARILLON) and Control groups</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the CARILLON Mitral Contour System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Optimized stable medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CARILLON Mitral Contour System</intervention_name>
    <description>Percutaneous mitral valve repair</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>CARILLON XE2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of dilated ischemic or non-ischemic cardiomyopathy

          -  Functional Mitral Regurgitation: 2+ (Moderate), 3+ (Moderate/Severe), or 4+ (Severe)

          -  New York Heart Association (NYHA) II, III, or IV

          -  Six Minute Walk distance of at least 150 meters and no farther than 450 meters

          -  Left Ventricular Ejection Fraction ≤ 50 %

          -  LV end diastolic dimension (LVEDD) &gt;55mm or LVEDD/Body Surface Area (BSA) &gt; 3.0cm/m2

          -  Stable heart failure medication regimen for at least three (3) months prior to index
             procedure

        Exclusion Criteria:

          -  Hospitalization in past three (3) months due to myocardial infarction, coronary
             artery bypass graft surgery, and/or unstable angina

          -  Hospitalization in the past 30 days for coronary angioplasty or stent placement

          -  Subjects expected to require any cardiac surgery within one (1) year

          -  Subjects expected to require any percutaneous coronary intervention within 30 days of
             enrollment

          -  Pre-existing device (e.g., pacing lead) in coronary sinus (CS) / great cardiac vein
             (GCV), or anticipated need for CRT within twelve (12) months

          -  Presence of a coronary artery stent under the CS / GCV in the implant target zone

          -  Presence of left atrial appendage (LAA) clot.

          -  Presence of primary renal dysfunction or significantly compromised renal function as
             reflected by a serum creatinine &gt; 2.2 mg/dL OR eGFR &lt; 30 ml/min

          -  Inability to undertake a six-minute walk test due to physical
             restrictions/limitations

          -  Chronic severe pathology limiting survival to less than 12-months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Sievert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardio Vascular Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kaye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nawzer Mehta, Ph.D.</last_name>
    <phone>+1 425 605 5922</phone>
    <email>nmehta@cardiacdimensions.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Arneson</last_name>
    <phone>+1 425 605 5966</phone>
    <email>jarneson@cardiacdimensions.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Straiton</last_name>
      <phone>+61 (0)2 9463 2402</phone>
      <email>Nicola.Straiton@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Ravinay Bhindi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wu</last_name>
      <phone>02 9515 8723</phone>
      <email>jun.wu@sswahs.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Mark Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Wollaston</last_name>
      <phone>+61 8 8204 4440</phone>
      <email>fiona.wollaston@sahmri.com</email>
    </contact>
    <investigator>
      <last_name>Carmine DePasquale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary-Anne Austin</last_name>
      <phone>+ 61 3 9594 4595</phone>
      <email>Maryanne.Austin@monashhealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Gooley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Mak</last_name>
      <email>V.Mak@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Stephen Duffy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olomouc University Hospital</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irena Opavská</last_name>
      <phone>+420 588 443 716</phone>
      <email>irena.opavska@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Milos Taborsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut klinické a experimentální medicíny (IKEM)</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kateřina Havlíková</last_name>
      <phone>+420 736 511 671</phone>
      <email>katerina.havlikova@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Josef Kautzner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liz Coling</last_name>
      <phone>+420 257272391</phone>
      <email>Liz.Coling@homolka.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Neuzil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle Sante République</name>
      <address>
        <city>Clermont Ferrand</city>
        <state>Auvergne</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Caillot</last_name>
      <phone>+33 (0)6 80 58 56 45</phone>
      <email>n.caillot@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Janusz Lipieck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Saint-Martin</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise Hupel</last_name>
      <email>fhupel.stmartin@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Francois Morelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique du Millénaire</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Bories</last_name>
      <phone>33 4.99.53.62.00</phone>
      <email>lisabor@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Piot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>European Hospital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Saidoun</last_name>
    </contact>
    <contact_backup>
      <phone>+33156092412</phone>
      <email>mohamed.saidoun@egp.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Spaulding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise Hupel</last_name>
      <email>fhupel@clinique-sainthilaire.fr</email>
    </contact>
    <investigator>
      <last_name>Jaques Berland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Touet</last_name>
      <phone>+33 2 32 88 83 79</phone>
      <email>Protocole-KT.Cardiologie@chiu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Durand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline Hupe</last_name>
      <phone>05 61 32 39 49</phone>
      <email>hupe.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Carrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Märkische Kliniken GmbH, Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <state>North Rhine-Westphalia</state>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Willms-Weirich</last_name>
      <phone>+49 (0) 2351-4665551</phone>
      <email>nicole.willms@klinikum-luedenscheid.de</email>
    </contact>
    <investigator>
      <last_name>Bernd Lemke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Kühn</last_name>
      <phone>+49 30 8445 4595</phone>
      <email>stefanie.kuehn@charite.de</email>
    </contact>
    <investigator>
      <last_name>Ulf Landmesser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta Kranken-Anstalt GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothee Henzler</last_name>
      <phone>+49 (0) 234 517-2446</phone>
      <email>henzler@augusta-bochum.de</email>
    </contact>
    <investigator>
      <last_name>Magnus Prull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmelo Smorta</last_name>
      <phone>49 69 / 6301-5710</phone>
      <email>Carmelo.smorta@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Fichtlscherer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardio Vascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine De Bruijn</last_name>
      <phone>+49 69 4600 3287</phone>
      <email>s.debruijn@cvcfrankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Horst Sievert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst GmbH</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Rahn</last_name>
      <phone>+49 69 3106-3806</phone>
      <email>Gabriele.Rahn@KlinikumFrankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Hans Ulrich Hink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Hobmaier</last_name>
      <email>beate.hobmaier@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Jochen Reinöhl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja Miodek</last_name>
      <phone>+49 451 585 1433</phone>
      <email>maja.miodek@sana.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Weil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus GmbH</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45661</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudiger Jegodka</last_name>
      <phone>+49 2361 601 6676</phone>
      <email>ruediger.jegodka@ekonline.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Lawo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Lousberg</last_name>
      <phone>+31-433874077</phone>
      <email>a.lousberg@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Jindrich Vainer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <zip>1030</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Burd</last_name>
      <phone>+ 64 9 307 4949</phone>
      <phone_ext>24365</phone_ext>
      <email>jburd@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Peter Ruygrok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Kalmucki, MD</last_name>
      <phone>+48605534009</phone>
      <email>pkalm@poczta.fm</email>
    </contact>
    <investigator>
      <last_name>Tomasz Siminiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harefield Hospital</name>
      <address>
        <city>Harefield</city>
        <state>Middlesex</state>
        <zip>UB9 6JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Rogers, RN</last_name>
      <phone>+49 01895-823737</phone>
      <phone_ext>3575</phone_ext>
      <email>p.rogers@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Mason, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <zip>LS2 9LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Somers</last_name>
      <phone>+44 (0) 113 3928483</phone>
      <email>kathryn.somers@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Christopher Malkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TBD</last_name>
    </contact>
    <investigator>
      <last_name>Mohaned Egred, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.cardiacdimensions.com/current-studies/</url>
    <description>Cardiac Dimensions - Current Clinical Studies</description>
  </link>
  <reference>
    <citation>Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, Levy WC, Mauri L, Feldman T, Kwong RY, Kaye DM, Duffy SJ, Tübler T, Degen H, Brandt MC, Van Bibber R, Goldberg S, Reuter DG, Hoppe UC. Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation. 2009 Jul 28;120(4):326-33. doi: 10.1161/CIRCULATIONAHA.109.849885. Epub 2009 Jul 13.</citation>
    <PMID>19597051</PMID>
  </reference>
  <reference>
    <citation>Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2012 Aug;14(8):931-8. doi: 10.1093/eurjhf/hfs076. Epub 2012 May 21.</citation>
    <PMID>22613584</PMID>
  </reference>
  <reference>
    <citation>Siminiak T, Hoppe UC, Schofer J, Haude M, Herrman JP, Vainer J, Firek L, Reuter DG, Goldberg SL, Van Bibber R. Effectiveness and safety of percutaneous coronary sinus-based mitral valve repair in patients with dilated cardiomyopathy (from the AMADEUS trial). Am J Cardiol. 2009 Aug 15;104(4):565-70. doi: 10.1016/j.amjcard.2009.04.021. Epub 2009 May 29.</citation>
    <PMID>19660613</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 26, 2017</lastchanged_date>
  <firstreceived_date>December 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional mitral regurgitation</keyword>
  <keyword>Secondary mitral regurgitation</keyword>
  <keyword>Percutaneous mitral repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
